Pre-Treatment Neutrophil-to-Lymphocyte Ratio (NLR) as a Predictive Marker of Pazopanib Treatment for Soft-Tissue Sarcoma

SIMPLE SUMMARY: Second-line systematic therapy options for soft-tissue sarcoma (STS) have remained unchanged for decades due to the rarity and various histological types associated with STS. Challenges with molecular-targeted treatments for STS led to the approval of pazopanib and its wide use for S...

Descripción completa

Detalles Bibliográficos
Autores principales: Sato, Yasuyoshi, Nakano, Kenji, Wang, Xiaofei, Fukuda, Naoki, Urasaki, Tetsuya, Ohmoto, Akihiro, Hayashi, Naomi, Yunokawa, Mayu, Ono, Makiko, Tomomatsu, Junichi, Saito, Masanori, Minami, Yusuke, Hayakawa, Keiko, Funauchi, Yuki, Tanizawa, Taisuke, Ae, Keisuke, Matsumoto, Seiichi, Takahashi, Shunji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699255/
https://www.ncbi.nlm.nih.gov/pubmed/34944888
http://dx.doi.org/10.3390/cancers13246266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699255/
https://www.ncbi.nlm.nih.gov/pubmed/34944888
http://dx.doi.org/10.3390/cancers13246266

Ejemplares similares